We are live on ! Find out more
BNGO icon

Bionano Genomics

108 hedge funds and large institutions have $32.1M invested in Bionano Genomics in 2023 Q2 according to their latest regulatory filings, with 28 funds opening new positions, 19 increasing their positions, 36 reducing their positions, and 45 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.02% less ownership

Funds ownership: 0.04%0.03% (-0.02%)

14% less funds holding

Funds holding: 126108 (-18)

27% less call options, than puts

Call options by funds: $525K | Put options by funds: $719K

38% less first-time investments, than exits

New positions opened: 28 | Existing positions closed: 45

47% less repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 36

65% less capital invested

Capital invested by funds: $90.6M → $32.1M (-$58.5M)

Holders
108
Holders Change
-18
Holders Change %
-14.29%
% of All Funds
1.7%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
28
Increased
19
Reduced
36
Closed
45
Calls
$525K
Puts
$719K
Net Calls
-$194K
Net Calls Change
-$1.05M
Name Holding Trade Value Shares
Change
Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$8.86M -$1.43M -3,157 -12%
BlackRock
2
BlackRock
New York
$3.74M -$12.9M -28,545 -74%
Qube Research & Technologies (QRT)
3
Qube Research & Technologies (QRT)
United Kingdom
$2.4M +$2.96M +6,566 New
State Street
4
State Street
Massachusetts
$2.34M -$5.16M -11,423 -64%
Mitsubishi UFJ Asset Management
5
Mitsubishi UFJ Asset Management
Japan
$2.19M +$1.91M +4,230 +241%
Millennium Management
6
Millennium Management
New York
$2.03M +$2.51M +5,551 New
Geode Capital Management
7
Geode Capital Management
Massachusetts
$1.82M -$2.11M -4,675 -48%
Mirae Asset Global Investments
8
Mirae Asset Global Investments
South Korea
$1.2M +$171K +378 +13%
Charles Schwab
9
Charles Schwab
California
$793K -$668K -1,480 -41%
Morgan Stanley
10
Morgan Stanley
New York
$667K -$1.41M -3,120 -63%
Northern Trust
11
Northern Trust
Illinois
$352K -$1.55M -3,437 -78%
ECM
12
ExodusPoint Capital Management
New York
$337K +$415K +920 New
Susquehanna International Group
13
Susquehanna International Group
Pennsylvania
$335K +$122K +271 +42%
Balyasny Asset Management
14
Balyasny Asset Management
Illinois
$325K -$33K -73 -8%
CF
15
Cantor Fitzgerald
New York
$305K +$376K +833 New
YIH
16
Y-Intercept (HK)
Hong Kong
$277K +$342K +757 New
ACS
17
Archford Capital Strategies
Illinois
$271K +$59.1K +131 +20%
Goldman Sachs
18
Goldman Sachs
New York
$268K -$19K -42 -5%
CSS
19
Cubist Systematic Strategies
Connecticut
$250K +$308K +682 New
IA
20
Inspire Advisors
Idaho
$241K +$15.3K +34 +5%
UBS AM
21
UBS AM
Illinois
$222K
Stifel Financial
22
Stifel Financial
Missouri
$203K -$1.81K -4 -0.7%
PMEF
23
Point72 Middle East FZE
United Arab Emirates
$197K +$243K +539 New
Bank of New York Mellon
24
Bank of New York Mellon
New York
$188K -$762K -1,688 -77%
E
25
Ergoteles
New York
$180K +$223K +493 New

BNGO Hedge Fund Activity: Q2 2023 in Review

108 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Bionano Genomics (BNGO) for Q2 2023, worth a combined $32.1M — down 65% from $90.6M a quarter earlier.

Sellers outnumbered buyers: 45 funds closed out of BNGO and 28 opened new positions — a net loss of 17 holders — while 36 trimmed existing stakes and 19 added.

The largest buyer was Qube Research & Technologies (QRT), opening a new position worth an estimated $2.96M. The largest seller was BlackRock, cutting an estimated $12.9M.

  • 108 institutional investors held Bionano Genomics (BNGO) as of Q2 2023, down from 126 in Q1 2023.
  • Funds reported $32.1M of Bionano Genomics stock for Q2 2023, down 65% quarter-over-quarter.
  • 28 funds opened new Bionano Genomics positions in Q2 2023 and 45 closed out, a net change of -17 holders.
  • The largest Bionano Genomics buyer in Q2 2023 was Qube Research & Technologies (QRT), an estimated $2.96M added.
  • The largest Bionano Genomics seller in Q2 2023 was BlackRock, an estimated $12.9M sold.

Based on aggregated 13F filings for Q2 2023.